MX341309B - Anticuerpos especificos del heterodimero de anti-il-23. - Google Patents
Anticuerpos especificos del heterodimero de anti-il-23.Info
- Publication number
- MX341309B MX341309B MX2013000727A MX2013000727A MX341309B MX 341309 B MX341309 B MX 341309B MX 2013000727 A MX2013000727 A MX 2013000727A MX 2013000727 A MX2013000727 A MX 2013000727A MX 341309 B MX341309 B MX 341309B
- Authority
- MX
- Mexico
- Prior art keywords
- specific antibodies
- heterodimer specific
- subunit
- present disclosure
- significantly bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un anticuerpo aislado o recombinante, o un fragmento de unión al antígeno de este que se une específicamente a IL-23 caracterizado porque comprende: una CDR1 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 8; una CDR2 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 9 o 22; una CDR3 de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID NO: 10; una CDR1 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 13; una CDR2 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 14; y una CDR3 de cadena ligera que comprende la secuencia de aminoácidos de la SEC ID NO: 15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010903234A AU2010903234A0 (en) | 2010-07-20 | Anti-IL-23 heterodimeric specific antibodies | |
US38494510P | 2010-09-21 | 2010-09-21 | |
PCT/AU2011/000923 WO2012009760A1 (en) | 2010-07-20 | 2011-07-20 | Anti-il-23 heterodimer specific antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013000727A MX2013000727A (es) | 2013-03-22 |
MX341309B true MX341309B (es) | 2016-08-12 |
Family
ID=45496377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000727A MX341309B (es) | 2010-07-20 | 2011-07-20 | Anticuerpos especificos del heterodimero de anti-il-23. |
Country Status (9)
Country | Link |
---|---|
US (1) | US9127057B2 (es) |
EP (1) | EP2596022A4 (es) |
JP (1) | JP5972871B2 (es) |
CN (1) | CN103108886B (es) |
AU (1) | AU2011282476B2 (es) |
CA (1) | CA2805653A1 (es) |
MX (1) | MX341309B (es) |
NZ (1) | NZ604415A (es) |
WO (1) | WO2012009760A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
RS55161B1 (sr) | 2010-11-04 | 2017-01-31 | Boehringer Ingelheim Int | Anti-il-23 antitela |
EP2844284A1 (en) | 2012-05-03 | 2015-03-11 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
US9708401B2 (en) * | 2012-05-22 | 2017-07-18 | Bristol-Myers Squibb Company | IL-17A/F cross-reactive monoclonal antibodies and methods of using the same |
WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
GB201214974D0 (en) * | 2012-08-22 | 2012-10-03 | Univ Edinburgh | Avian proteins, nucleic acids and uses thereof |
AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
EP2968500A4 (en) * | 2013-03-15 | 2016-06-29 | Univ Pennsylvania | VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS |
JP2016517408A (ja) | 2013-03-15 | 2016-06-16 | アムジェン インコーポレイテッド | 抗il−23抗体を用いた乾癬の治療方法 |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
BR112017004169A2 (pt) | 2014-09-03 | 2017-12-05 | Boehringer Ingelheim Int | composto direcionado à il-23a e ao tnf-alfa e usos do mesmo |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
CA2998349A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
CA3003539A1 (en) * | 2015-10-30 | 2017-05-04 | Ablynx Nv | Polypeptides against il-23 |
KR20180096633A (ko) | 2015-12-22 | 2018-08-29 | 암젠 인크 | Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20 |
IL267113B1 (en) * | 2016-12-21 | 2024-05-01 | Cephalon Llc | Antibodies that bind specifically to human IL-15 and their uses |
CN112689643A (zh) | 2018-07-13 | 2021-04-20 | 阿斯特捷利康合作创业有限责任公司 | 用布雷库单抗治疗溃疡性结肠炎 |
CN109970855A (zh) * | 2019-04-12 | 2019-07-05 | 深圳普瑞金生物药业有限公司 | Il23单域抗体的vhh链、il23单域抗体、核苷酸序列及试剂盒 |
CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
DE4211351A1 (de) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
AU3691093A (en) | 1992-04-14 | 1993-10-21 | Hybritech Incorporated | Methods of inhibiting the growth of multidrug resistant tumors |
US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US6291189B1 (en) | 1994-05-10 | 2001-09-18 | Carta Proteomics, Inc. | Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
US6562622B1 (en) | 1998-05-08 | 2003-05-13 | Diatech Pty, Ltd | Continuous in vitro evolution |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
EP1159611A1 (en) | 1999-01-15 | 2001-12-05 | Medtox Scientific Inc. | Lateral flow test strip |
US7270969B2 (en) | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
AU2002331408B2 (en) | 2001-08-20 | 2008-05-08 | Proteome Systems Ltd | Diagnostic testing process and apparatus |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US20040265926A1 (en) | 2002-11-21 | 2004-12-30 | Leong Ng | Bodily fluid markers of tissue hypoxia |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
CA2525184C (en) * | 2003-05-09 | 2012-10-30 | Centocor, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
CA2527726A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変 |
AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
WO2006102720A1 (en) | 2005-03-31 | 2006-10-05 | Telethon Institute For Child Health Research | Isolation of inhibitor of ires-mediated translation |
AU2006265002B2 (en) * | 2005-06-30 | 2012-09-20 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
US7196172B2 (en) | 2005-07-15 | 2007-03-27 | Zymogenetics, Inc. | Heterodimeric four helix bundle cytokines |
KR20080068004A (ko) | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
PT1931710T (pt) | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
MX2011001409A (es) * | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
MX2011002159A (es) | 2008-08-27 | 2011-03-29 | Schering Corp | Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria. |
AR074369A1 (es) | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
-
2011
- 2011-07-20 AU AU2011282476A patent/AU2011282476B2/en not_active Ceased
- 2011-07-20 EP EP11809081.0A patent/EP2596022A4/en not_active Withdrawn
- 2011-07-20 US US13/810,474 patent/US9127057B2/en not_active Expired - Fee Related
- 2011-07-20 CA CA2805653A patent/CA2805653A1/en not_active Abandoned
- 2011-07-20 JP JP2013519918A patent/JP5972871B2/ja not_active Expired - Fee Related
- 2011-07-20 WO PCT/AU2011/000923 patent/WO2012009760A1/en active Application Filing
- 2011-07-20 MX MX2013000727A patent/MX341309B/es active IP Right Grant
- 2011-07-20 NZ NZ604415A patent/NZ604415A/en not_active IP Right Cessation
- 2011-07-20 CN CN201180036330.0A patent/CN103108886B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX2013000727A (es) | 2013-03-22 |
JP2013535191A (ja) | 2013-09-12 |
US9127057B2 (en) | 2015-09-08 |
CN103108886B (zh) | 2016-08-24 |
CN103108886A (zh) | 2013-05-15 |
AU2011282476B2 (en) | 2015-08-20 |
CA2805653A1 (en) | 2012-01-26 |
NZ604415A (en) | 2014-10-31 |
JP5972871B2 (ja) | 2016-08-17 |
AU2011282476A1 (en) | 2013-01-10 |
EP2596022A1 (en) | 2013-05-29 |
WO2012009760A1 (en) | 2012-01-26 |
EP2596022A4 (en) | 2014-11-05 |
US20130115166A1 (en) | 2013-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341309B (es) | Anticuerpos especificos del heterodimero de anti-il-23. | |
AU2018260863A1 (en) | Human IgG1 Fc region variants and uses thereof | |
PH12014502527A1 (en) | St2 antigen binding proteins | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
EP4219552A3 (en) | Il-11r binding proteins and uses thereof | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
MX357944B (es) | Variantes anticuerpos y usos de las mismas. | |
MY162752A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
AU2009260320A8 (en) | Antibodies to IL-6 and their uses | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
NZ720765A (en) | Antibodies and methods of use | |
WO2012064836A9 (en) | Methods and compositions for neural disease immunotherapy | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
MX2010001237A (es) | Nuevos anticuerpos. | |
WO2011085165A3 (en) | Ca-125 immune complexes as biomarkers of ovarian cancer | |
WO2015006337A3 (en) | Compositions and methods for increasing protein half-life in a serum | |
MX343580B (es) | Anticuerpos contra el g-csfr y sus usos. | |
WO2010136483A3 (en) | Antigen-binding proteins | |
EP3773716A4 (en) | MONOCLONAL ANTIBODIES THAT BIND TO SSEA4 AND THEIR USES | |
UA109148C2 (uk) | Композиції на основі антитіла проти vegfr-3 | |
MX2021015473A (es) | Nuevo anticuerpo específico para cthrc1 y su uso. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
PH12014502468A1 (en) | Methods for identifying immunobinders of cell-surface antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |